Christopher M. Cashman
EVP and Chief Commercialization Officer, MiMedx Group, Inc.

Christopher  M.  Cashman  joined  MiMedx  as  the  Company’s  Executive  Vice  President  &  Chief Commercialization Officer in November 2014.  In his role, Mr. Cashman will contribute his expertise to the Company’s global sales & marketing functions, strategic planning and all related revenue growth initiatives.  Most recently, Mr. Cashman was President and Chief Executive Officer of SANUWAVE Health, a regenerative medicine company focused on the development and commercialization of Extracorporeal Shock Wave Technology for chronic wound care, orthopaedic, cardiovascular and plastic surgery. Before joining SANUWAVE, he served as President of Therapeutic Surfaces for Kinetic Concepts, Inc. (KCI), a worldwide leader in advanced wound healing products.  Prior to that, Mr. Cashman was President and Chief Executive Officer for Snowden Pencer, a manufacturer of minimally invasive devices and specialty surgical instrumentation.  He successfully led a management buyout of Snowden Pencer from Genzyme in 2001, and the business was sold in 2004 to Cardinal Health.  Mr. Cashman also held various sales, marketing and general management positions within divisions of Genzyme Biosurgery and Deknatel. Following his graduation from the United States Naval Academy, Mr. Cashman served as Supply Officer on the USS Trepang, a fast attack nuclear submarine.  Mr. Cashman is also an Industry Fellow and Advisor to the Georgia Research Alliance (GRA) where he guides and assists GRA Venture supported University research and early stage companies to aid in building successful businesses in the medical sciences and technology fields. He is also a Board Director for Bio/Med Investor Network.  Mr. Cashman holds an MBA from Northwestern University’s Kellogg Graduate School of Management, and is a graduate of the United States Naval Academy, where he received a Bachelor’s of Science in Economics